Palisade Bio, Inc. (Ticker: PALI), formerly known as Seneca Biopharma, Inc., is a clinical-stage biopharmaceutical company that focuses on the development of novel therapeutics for major unmet medical needs, particularly in the area of gastrointestinal (GI) health. Centred on transforming the way clinicians treat and prevent damaging GI conditions, this forward-thinking company is committed to the evolution and progress of healthcare solutions.
Headquartered in Carlsbad, California, USA, Palisade Bio, Inc. was initially incorporated in 1986, and has been in business under its current name since February 2021. The company has a history filled with innovation, bold initiatives, and strategic partnerships – a testament to its commitment to its mission and vision.
The company’s lead product candidate, LB1148, is a novel compound designed to hasten the return of bowel function and decrease post-surgery complications. LB1148 is an oral formulation with a Phase 3 clinical trial for usage in the postoperative ileus (POI) setting, an inevitable GI dysfunction after abdominal surgery. In addition to this, the company is also involved in producing a valuable product pipeline from the GI therapeutics area.
The company’s research and development activities represent a potentially significant leap in post-surgery patient care. Postoperative ileus is known to prolong hospital stays and cause severe discomfort to the patient, highlighting the importance of Palisade Bio's work in the healthcare industry.
The leadership team at Palisade Bio, Inc. is composed of specialists with significant experience across the pharmaceutical industry. These experts bring a diverse range of experiences and skills-sets to the company, enabling innovative thinking and a strategic approach to tackling healthcare challenges.
With a focus on the betterment of patient care and a dedication to developing innovative drugs to enhance healthcare, the work of Palisade Bio, Inc. stands as an important contribution to the pharmaceutical industry. Their approach toward treatment of GI dysfunctions through innovative therapeutics signifies their commitment to exploring new paradigms in the healthcare sector.
In conclusion, Palisade Bio, Inc. (PALI) is more than just another biopharmaceutical company. It represents a beacon of continuous innovation and a tireless dedication to improving the lives of patients around the globe. With its robust portfolio and unyielding commitment to science and health, Palisade Bio is paving the way forward in biopharmaceutical research and product development.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Palisade Bio, Inc. has announced that the first patient has been dosed in its global Phase 2b ASCENTRA-UC clinical trial for PALI-2108, an investigational oral therapy for moderately to severely active ulcerative colitis. PALI-2108 is a gut-activated PDE4 inhibitor prodrug designed to improve tolerability and deliver meaningful disease control, with topline induction results expected in Q4 2027. The study aims to evaluate the efficacy and safety of two once-daily dose levels of PALI-2108 across approximately 204 patients.
Oppenheimer analyst Leland Gershell has maintained a Buy rating on Palisade Bio (PALI) with a price target of $8.00, citing the company's prospects in the Healthcare sector. This rating is consistent with the Strong Buy consensus among analysts, who have an average price target of $10.17 for Palisade Bio. The company recently reported a quarterly revenue of $500 thousand but also a GAAP net loss of $10.57 million for the quarter ending June 30.
Palisade Bio announced positive clinical and translational findings for its investigational oral therapy PALI-2108 in inflammatory bowel disease at UEG Week 2026. The data showed rapid endoscopic improvement and reduced inflammation in patients with fibrostenotic Crohn's disease and ulcerative colitis, along with strong evidence of targeted drug delivery. These results support the advancement of PALI-2108 as a once-daily oral treatment, with Phase 2b and Phase 2a studies currently enrolling or being initiated.